AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensit...